HRP20201815T1 - Nukleinske kiseline za liječenje alergija - Google Patents

Nukleinske kiseline za liječenje alergija Download PDF

Info

Publication number
HRP20201815T1
HRP20201815T1 HRP20201815TT HRP20201815T HRP20201815T1 HR P20201815 T1 HRP20201815 T1 HR P20201815T1 HR P20201815T T HRP20201815T T HR P20201815TT HR P20201815 T HRP20201815 T HR P20201815T HR P20201815 T1 HRP20201815 T1 HR P20201815T1
Authority
HR
Croatia
Prior art keywords
nucleic acid
seq
acid molecule
treatment
pharmaceutical composition
Prior art date
Application number
HRP20201815TT
Other languages
English (en)
Croatian (hr)
Inventor
William Hearl
Teri Heiland
Original Assignee
Immunomic Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics, Inc. filed Critical Immunomic Therapeutics, Inc.
Publication of HRP20201815T1 publication Critical patent/HRP20201815T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HRP20201815TT 2012-06-15 2012-06-15 Nukleinske kiseline za liječenje alergija HRP20201815T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12878776.9A EP2861240B1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies
PCT/US2012/042552 WO2013187906A1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Publications (1)

Publication Number Publication Date
HRP20201815T1 true HRP20201815T1 (hr) 2021-02-19

Family

ID=49758576

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201815TT HRP20201815T1 (hr) 2012-06-15 2012-06-15 Nukleinske kiseline za liječenje alergija

Country Status (20)

Country Link
US (3) US9744230B2 (OSRAM)
EP (2) EP2861240B1 (OSRAM)
JP (1) JP5807994B2 (OSRAM)
KR (2) KR102107646B1 (OSRAM)
CN (2) CN107937423A (OSRAM)
AU (3) AU2012382406B2 (OSRAM)
BR (1) BR112014031327B1 (OSRAM)
CA (1) CA2876824C (OSRAM)
CY (1) CY1123769T1 (OSRAM)
DK (1) DK2861240T3 (OSRAM)
ES (1) ES2831723T3 (OSRAM)
HR (1) HRP20201815T1 (OSRAM)
HU (1) HUE052481T2 (OSRAM)
IL (4) IL236174B (OSRAM)
LT (1) LT2861240T (OSRAM)
PL (1) PL2861240T3 (OSRAM)
PT (1) PT2861240T (OSRAM)
RS (1) RS61098B1 (OSRAM)
SI (1) SI2861240T1 (OSRAM)
WO (1) WO2013187906A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
RS61098B1 (sr) 2012-06-15 2020-12-31 Immunomic Therapeutics Inc Nukleinske kiseline za lečenje alergija
CN105120894B (zh) 2012-10-30 2019-02-15 阿拉沃克斯有限公司 新颖的免疫治疗分子和其用途
JP7007534B2 (ja) 2013-09-25 2022-01-24 アラヴァックス ピーティーワイ リミテッド 新規免疫療法組成物およびその使用
BR112016030439A2 (pt) * 2014-06-23 2018-07-17 Immunomic Therapeutics Inc ácidos nucléicos para o tratamento de alergias ao amendoim.
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
KR20180093954A (ko) 2015-12-23 2018-08-22 메디진 이뮤노테라피스 게엠바하 항원-특이적 tcr의 신규 생성
EP3541420A2 (en) 2016-11-16 2019-09-25 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
JP7610349B2 (ja) * 2017-04-22 2025-01-08 イミュノミック セラピューティックス， インコーポレイテッド 改良ｌａｍｐ構築物
KR20200016224A (ko) * 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
SG11202000419QA (en) 2017-07-18 2020-02-27 Before Brands Inc Methods for making mixed allergen compositions
CA3096363C (en) * 2018-04-06 2024-04-16 Slsbio Co., Ltd. Novel epitope of immunoglobulin e, antibody binding thereto, and kit for analyzing immunoglobulin e in sample containing same
WO2019216396A1 (ja) 2018-05-11 2019-11-14 アステラス製薬株式会社 甲殻類アレルギー治療のための核酸
WO2019216394A1 (ja) 2018-05-11 2019-11-14 アステラス製薬株式会社 ダニアレルギー治療のための核酸
WO2019222281A1 (en) * 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc Improved lamp constructs comprising allergens
SG11202108043PA (en) 2019-01-23 2021-08-30 Before Brands Inc Methods for making mixed allergen compositions
KR102811748B1 (ko) * 2019-03-13 2025-05-26 주식회사 마크로젠 알레르기 치료를 위한 에피토프-기반 접근법 및 크론병에 대한 억제제
JP2024517463A (ja) * 2021-05-04 2024-04-22 ソヴィダ ソリューションズ リミテッド ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法
WO2023013785A1 (ja) * 2021-08-06 2023-02-09 花王株式会社 Ｓｎａｒｅを活用した核酸構築物
FI20237105A9 (en) 2023-05-29 2024-11-30 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic action and greater survival

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD335810S (en) 1990-07-02 1993-05-25 Dick-Ming Asien Handle for luggage or similar article
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6090386A (en) 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
NZ258701A (en) 1992-11-12 1996-11-26 Immulogic Pharma Corp Allergenic cry j ii proteins and coding sequences from japanese cedar pollen, their production and therapeutic use
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP3649460B2 (ja) 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
WO1997024139A1 (en) 1995-12-29 1997-07-10 University Of Arkansas Peanut allergens and methods
CN102286077A (zh) 1996-06-14 2011-12-21 明治乳业株式会社 T细胞表位肽
EP1278550A4 (en) * 2000-04-07 2004-05-12 Univ California SYNERGISTIC IMPROVEMENTS OF POLYNUCLEOTIDE VACCINE
WO2002074250A2 (en) 2001-03-16 2002-09-26 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
WO2002080851A2 (en) 2001-04-05 2002-10-17 The Johns Hopkins University Chimeric vaccines
US20060003148A1 (en) 2004-06-30 2006-01-05 Zwynenburg James L Interlocking polymeric foam floor underlayment and process for making
US20060216315A1 (en) * 2005-03-16 2006-09-28 Yoo Tai J Cockroach allergen gene expression and delivery systems and uses
US20090304738A1 (en) 2005-06-16 2009-12-10 Moran Thomas M Methods for Enhancing Immune Responses
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
EP1932538A4 (en) * 2005-08-25 2009-10-21 Taiho Pharmaceutical Co Ltd BIODEGRADABLE NANOPARTICLE HAVING RECYCLABLE IMMUNIZED T-EPITOPE PEPTIDE IMMOBILIZED ON OR ENCAPSULATED THEREIN
US20080006554A1 (en) 2006-07-07 2008-01-10 Medtronic Vascular, Inc. Packaging assembly for a catheter
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
EA023912B1 (ru) * 2008-09-10 2016-07-29 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительных состояний
RS61098B1 (sr) * 2012-06-15 2020-12-31 Immunomic Therapeutics Inc Nukleinske kiseline za lečenje alergija
EP3541420A2 (en) * 2016-11-16 2019-09-25 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
JP7610349B2 (ja) * 2017-04-22 2025-01-08 イミュノミック セラピューティックス， インコーポレイテッド 改良ｌａｍｐ構築物

Also Published As

Publication number Publication date
PL2861240T3 (pl) 2021-07-05
RS61098B1 (sr) 2020-12-31
EP2861240A1 (en) 2015-04-22
AU2019250227B2 (en) 2021-10-21
EP3808361A1 (en) 2021-04-21
US10072053B2 (en) 2018-09-11
KR20200047792A (ko) 2020-05-07
IL270262A (en) 2019-12-31
CA2876824A1 (en) 2013-12-19
IL236174A0 (en) 2015-01-29
AU2018200625A1 (en) 2018-02-15
AU2019250227A1 (en) 2019-11-07
IL236174B (en) 2019-11-28
CN107937423A (zh) 2018-04-20
CN104519896A (zh) 2015-04-15
EP2861240B1 (en) 2020-09-09
IL270260B (en) 2020-08-31
WO2013187906A1 (en) 2013-12-19
CY1123769T1 (el) 2022-05-27
JP5807994B2 (ja) 2015-11-10
PT2861240T (pt) 2020-11-09
BR112014031327B1 (pt) 2022-02-01
CN104519896B (zh) 2017-11-10
US20160271245A1 (en) 2016-09-22
KR102386481B1 (ko) 2022-04-14
IL270261B (en) 2021-03-25
US9744230B2 (en) 2017-08-29
AU2012382406B2 (en) 2017-12-07
LT2861240T (lt) 2021-01-25
US20180009857A1 (en) 2018-01-11
US20220081474A1 (en) 2022-03-17
AU2012382406A1 (en) 2014-12-18
AU2018200625B2 (en) 2019-09-19
DK2861240T3 (da) 2020-09-28
BR112014031327A2 (pt) 2017-06-27
CA2876824C (en) 2020-07-21
KR102107646B1 (ko) 2020-05-08
AU2012382406A2 (en) 2015-04-16
JP2015521467A (ja) 2015-07-30
SI2861240T1 (sl) 2021-04-30
EP2861240A4 (en) 2016-03-16
HUE052481T2 (hu) 2021-04-28
ES2831723T3 (es) 2021-06-09
KR20150032286A (ko) 2015-03-25

Similar Documents

Publication Publication Date Title
HRP20201815T1 (hr) Nukleinske kiseline za liječenje alergija
CY1122195T1 (el) Πολυπεπτιδια συντηξης σερπινης και μεθοδοι χρησης αυτων
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
WO2010150233A3 (en) Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
BR112013029409A8 (pt) produtos farmacêuticos de peptídeo melhorados para resistência à insulina
EA201170635A1 (ru) Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
BR112014019901A8 (pt) Proteínas de fator viii recombinante
CO6690759A2 (es) Anticuerpos, fragmentos de unión o derivados de los mismos que se unen específicamente a la proteína 4-1 bb
HRP20192314T1 (hr) Pripravci faktora viii i postupci pripreme i njihove uporabe
GT200500254A (es) Proceso para la concentracion de anticuerpos y productos terapeùticos relacionados.
DK2027152T3 (da) Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner
UA107571C2 (xx) Фармацевтична композиція
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
BR112015003947A8 (pt) Proteínas de fusão e métodos para tratar, prevenir ou melhorar dor
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
MX2014007516A (es) Procesos que utilizan vlps con capsides resistentes a hidrolasas.
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
CO6210831A2 (es) Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal
RU2015126105A (ru) Модифицированные суперспиральные белки с улучшенными свойствами
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
US20160362454A1 (en) Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses